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INTRODUCTION 
 
Cardiovascular disease has emerged as one of the leading cause of death in women, 
resulting in the death of one in three women, irrespective of race and ethnicity. 
A growing body of research based on gender influence in cardiovascular disease is 
elucidating the differences between men and women. Be it clinical presentation or the 
response to treatment, the profile variation between the two sexes are profound. 
Women with ACS more commonly present with non cardiac chest pain, have negative 
cardiac biomarkers and are usually referred for treatment late. Despite of a lower 
incidence of STEMI in women than men, the morbidity and mortality rates are 
significantly higher in women. This can be partly attributed to the delay in treatment 
due to the lack of awareness and less aggressive treatment being offered to women 
which is evidenced by the low rates of PCI in women. 
The influence of sex-age interaction on mortality rates in cardiovascular disease have 
long been under study. Various researches have proven that younger women had a 
higher in patient mortality than men of the same age. As compared to young men, the 
prevalence of DM, CHF and late presentation was higher in young women. In addition 
to this, they had a higher chance of developing complications. 
Most of our knowledge on MI and treatment profile has been developed from studies 
which focused mainly on men. In the present scenario, it is important to understand 
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the subtle differences in the development and progression of disease in men and 
women. Most of these differences can be attributed to age and the prevalence of co 
morbidities. Therein lay the supreme need to identify those risk factors which 
predispose women to cardiovascular disease and implement this knowledge in our day 
to day out patient practice. 
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AIMS AND OBJECTIVES 
 
 The study is designed to evaluate the frequency of prevalent risk factors of 
ACS in females admitted in the medicine casualty of Thanjavur Medical 
College 
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REVIEW OF LITERATURE 
 
ANATOMY 
The borders of the heart: 
Right border of the heart corresponds to right atrium and is in line with the SVC 
and IVC. 
Left border of the heart is comprised mainly by the left atrium. The left auricular 
appendages  also contribute a little to it. 
The right ventricle and a portion of the left ventricle form the inferior border. 
Four veins (right & left pulmonary veins) open into the left atrium. 
Diagram no: 1) borders of the heart 
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Blood supply of the heart 
The major blood supply is by the right & left coronary arteries which are branches 
of the ascending aorta. 
Diagram no: 3 
 
                                                                                       .                              
 
 
 
 
RCA lies in the coronary sulcus & anastomose with left circumflex artery on the posterior aspect 
Branches: large - marginal, posterior, inter ventricular 
                   Small- nodal, R .atrial , infundibular , terminal 
Areas of distribution : right atrium, right ventricle except area adjoining anterior inter ventricular 
groove ,posterior part of inter ventricular septum, conducting system of heart except left branch of 
AV bundle . 
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Diagram no: 4 
 
 
LCA  
Branches: large – diagonal, anterior inter ventricuar 
                   Small- left atrial, pulmonary, terminal 
Areas of distribution: left atrium, left ventricle except area adjoining posterior inter ventricular 
groove , anterior part of inter ventricular septum ,left branch of AV bundle, small part of right 
ventricle adjoining anterior inter ventricular groove 
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The dominant system of blood supply is the one which gives off the posterior inter 
ventricular branch. Most commonly it is the left coronary artery in 70 - 75% of the 
people. 
In fetal life, the coronary arteries are supplemented by a rich supply of collaterals. 
In contrast, adult coronary arteries are end arteries, collaterals develop during 
chronic hypoxia. 
                                               MYOCARDIAL INFARCTION 
 
Myocardial infarction refers to ischemic necrosis of the heart muscles 
(myocardium).There is a mismatch between the oxygen demand and blood supply to 
the area 
 
In 2001, the American College of Cardiology issued a recommendation for the 
diagnosis of Acute MI replacing the old version of World Health Organization 
definition.  
The rise and fall of cardiac markers (CK-MB, Troponin) in addition to: 
 Typical symptoms of  MI like angina, palpitations, diaphoresis 
 ST depression/ elevation in the electrocardiogram 
 New onset pathological deep Q waves 
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Autopsy findings suggestive of MI are also considered diagnostic. Additionally 
STEMI can be diagnosed in a patient presenting with typical clinical symptoms of MI 
along with new onset left bundle branch block. However distinction between UA and 
NSTEMI may prove difficult in the first few hours within the onset of the event since 
detectable elevations in cardiac makers may not be apparent during that time period. 
So serial measurements are required. 
Revised Definition of Myocardial Infarction (MI)  
A. Criteria for Acute, Evolving, or Recent MI 
1. Typical rise and/or fall of biochemical markers of myocardial necrosis with at least 
one of the following 
A) Ischemic symptoms 
B) Development of pathological Q waves in the ECG 
C) ECG changes indicative of ischemia (ST segment elevation or depression) 
D) Imaging evidence of new loss of viable myocardium or new regional wall 
Motion abnormality 
2. Pathological findings of an acute myocardial infarction
. (1)
 
(Either of the above criteria satisfies the diagnosis for acute, evolving or recent MI) 
B. Criteria for Healing or Healed Myocardial Infarction: 
1. Development of new pathological Q waves in serial ECGs. The patient may or may 
not remember previous symptoms. Biochemical markers of myocardial necrosis may 
have normalized depending on the length of time that has passed since the infarction 
developed. 
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2. Pathological findings of a healed or healing infarction. 
(Any one of the above criteria satisfies the diagnosis for healing or healed MI) 
 
Ischemic heart disease is caused either by obstruction in the blood flow or increase in 
oxygen demand caused by cardiac chamber hypertrophy. 
 The commonest cause is atherosclerosis which can cause obstruction or narrowing of 
a coronary artery sufficient to reduce blood flow and inadequate perfusion to that area. 
 
Despite the above data, studies have shown declining mortality in IHD which can be 
attributed to the improvement in health facilities and increasing awareness among the 
general public. 
(2)
 
The modifiable risk factors for myocardial infarction include a sedentary lifestyle 
,high calorie diet and obesity .Familial hyperlipidemia , insulin resistance ,type 2 DM, 
hypertension are important risk factors for MI. Highest susceptibility is seen among 
the southeast Asian countries 
Pathophysiology 
Causes of Acute MI:  
 
                                                                            
 
 
 
3) Arteritis                                                                                                      
4) Intimal proliferative diseases-   
  Homocystinemia  
 Fabrys disease  
  Amyloidosis  
 Aortic Dissection  
 
 Juvenile intimal sclerosis  
  Oral contraceptive pills  
 Mucopolysaccharidoses 
1) Luminal narrowing  
 prinzmetals angina ; spasm without 
thrombus  
 Nitroglycerin withdrawal  
2)  Aortic Dissection  
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Pathophysiology of atherosclerosis 
 
Since it is the most important cause, it is essential to describe atherosclerosis in detail 
The pathognomonic feature of atherosclerosis is the atheroma or atherosclerotic 
plaque. Histopathology shows  
 Fibrotic cap 
 Cellular area around cap having macrophages ,smooth muscles and T 
lympocytes 
 Necrotic core 
 
Coronary artery Embolism  
 Acute bacterial endocarditis  
 Libman sachs and marantic endocarditis  
 left ventricular stasis/ thrombus  
 Cardiac tumours  
 Post procedures like CABG and PTCA  
 
Congenital anomalies  
 ALCAPA  
 
Myocardial oxygen demand-supply 
mismatch 
 
 Aortic stenosis,  
 Cardiac chamber hypertrophy  
 Severe anemia  
 Pagets disease  
 Cardiogenic shock  
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Diagram no: 5 image of an atheromatous plaque 
 
Chronic endothelial injury results in increased permeability, leukocyte adhesion and 
thrombotic potential. This is associated with accumulation of lipoproteins and its 
oxidation in the vessel walls. This further leads to more accumulation of monocytes 
which adhere to the vessel wall and transform into macrophages and foam cells inside 
the intima along with adhesion of platelets.  
Diagram no 6: pathophysiology of atheromatous plaque 
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The activated platelets release factors causing migration of smooth muscles from 
media to the intima and their proliferation along with deposition of proteoglycans and 
collagen. This results in enhanced accumulation of lipids. The metallo proteinases 
causes thinning and erosion of the fibrous cap, resulting in luminal narrowing/ 
occlusion
. (3)
 
PLAQUE STABILITY 
There are 3 factors which determine plaque stability  
 Mechanical stress 
 Inflammatory triggers 
 Weakening of the fibrotic cap(which can be caused by different factors) 
Diagram no 7 
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Mechanical stress 
Stress felt by the atheromatous plaque is dependent on several factors. One is the 
thickness of the cap. A relative thin cap is seen in moderate stenosis as compared to 
severe stenosis, so moderate stenosis has to endure more stress. The lipid pool 
overlying the cap is also important. Along with the quantity of lipid pool, the nature 
of accumulated lipids is also important. Softer plaques withstand mechanical stress 
poorly. The softness is determined by the ratio of cholesterol esters to monohydrate 
cholesterol as well as the size of the necrotic lipid rich core of a plaque relative to the 
size and thickness of the cap
.(4)
 
Weakening of the cap 
 Reduced collagen synthesis by smooth muscle cells in the vulnerable region of 
plaques 
The collagenous framework of the plaque’s fibrotic cap plays a crucial role in 
maintaining the strength of the cap. The immune and inflammatory factors disturb 
the framework by the secretion of IFN-gamma which inhibits collagen synthesis. 
 Increased collagen degradation 
Normal human arteries do not have MMPs, which are capable of breaking down 
interstitial collagen. However, certain cells in the atheroma secrete MMPs 1, 8 and 13 
and they are capable of degrading collagen in situ 
 Enhanced smooth muscle death 
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As mentioned earlier, inflammatory mediators like interferon gamma secreted by 
activated T cells inhibit collagen synthesis and smooth muscle replication. Along 
with this, certain pro-inflammatory mediators like interleukin 1 beta and tumor 
necrosis factor can promote apoptosis of smooth muscle cells. These pro-
inflammatory mediators can also cause programmed cell death of endothelial cells 
and lysis of basement membrane (type IV collagen by collagenases especially MMP 
2) 
These are potential mechanisms of superficial erosions being formed on plaques and 
thereby stimulate platelet adhesion. 
 Inflammatory triggers 
Active inflammation plays a major role in the chronic pathogenesis of atherosclerosis 
.Many patients with severe and extensive atherosclerosis remain stable for many 
years, while some patients present with severe and acute complications of ACS as the 
first manifestation. This exposes our relative lack of knowledge about the 
inflammatory triggers that bring about acute complications of ACS. 
A large part of vessel wall is composed by the media and adventitia and perfused by  
vasa vasorum. These vessels undergo proliferation in atheromatous lesions.  
Angiogenic factors like vascular endothelial growth factor, transforming growth 
factor etc are secreted at the site of lesions in response to local stress, intramural 
hypoxia, inflammation and apoptosis .These factors cause proliferation and sprouting 
of new vessels in and around the atheromatous plaques 
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Initially, these neo-vessels serve as a compensatory mechanism to counteract local 
hypoxia and helps restoring oxygen availability and resolving inflammation. Recent 
works have revealed that these immature neo-vessels which lack basement membrane 
are a potential precipitating factor for ACS. It causes intra plaque hemorrhage , 
leading to rapid plaque expansion and fuels inflammation. 
Activated inflammatory cells secrete pro inflammatory cytokines which promote neo-
vascularisation, leakage of blood and generation of free Hb. If this free Hb is not 
rapidly bound by haptoglobin  and  subsequently cleared by CD163 positive 
macrophages ,a sudden surge of oxidative stress occurs. Reactive oxygen species 
which overwhelm the local radical scavenging mechanisms are produced. This leads 
to further leukocyte activation and the vicious cycle continues. 
Research groups like Yunoki et al have made an important observation that 
neutrophils were specific for unstable plaques. Telomerase enzyme in neutrophils of 
unstable show transient activation; this is not seen in stable plaques. Similarly 
differences in T lymphocytes have also been reported. 
The greatest challenge of the future would be to determine those specific triggers 
which can destabilize a plaque and initiate the dreaded complications of ACS. 
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 RISK FACTORS FOR ATHEROSCLEROSIS 
NONMODIFIABLE  
 
1) Elderly (men >45 & women > 55) 
2) Male gender  
3) Family history of early onset CAD (at 
age less than 55 years)  
4) Genetic abnormalities  
 
MODIFIABLE  
1) Hyperlipidemia  
 Total cholesterol > 150mg%  
 Triglycerides > 150 mgs%  
 LDL cholesterol > 100 mg%  
 APO – b lipoproteins >100 mg %  
 HDL cholesterol < 40 mg% males, 
< 50 mg% females.  
2) Hypertension  
3) Cigarette smoking  
4) Diabetes Mellitus  
5) C-reactive protein  
6) BMI > 22  
7) Homocysteine > 10 micro mol/lit  
 
 
 
Stages of atherosclerosis 
 
Early atherosclerosis  
Subtle atherosclerosis  
Advance atherosclerosis  
Unstable coronary plaque
 (5)
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Diagram no 8: natural history of atherosclerosis
 
VIRCHOW’S TRIAD IN THROMBOSIS  
 
The concept of Virchow’s triad plays an important role in coronary thrombosis too. It 
consists of 
 Hypercoagulable state               
 Blood flow stasis 
 Vessel wall injury 
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Diagram no 9: microscopic picture of a plaque rupture.  Hematoxylin and eosin stain, 
showing occlusive thrombus overlying atheroma with rupture on shoulder ( arrow) 
and communication of thrombus with atheroma core. 
 
NATURAL HISTORY OF MYOCARDIAL INFARCTION 
The clinical picture of acute coronary syndrome may vary depending upon the fate of 
the ruptured atherosclerotic plaque (7)  
 Complete occlusion results in trans mural (ST elevation) MI  
 Partial occlusion results in unstable angina / non ST elevation MI  
 Sometimes spontaneous resolution can occur  
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HAEMODYNAMIC ALTERATIONS  
Myocardial infarction results in decreased contractility of heart and there by reduced 
stroke volume that stimulates the baroreceptors to increase the sympathetic outflow. 
This sympathetic surge increases the heart rate, increases after load, and decreases the 
diastolic filling, resulting in a vicious cycle. 
(6)
 
Classification of MYOCARDIAL INFARCTION 
 Type 1: spontaneous myocardial infarction. 
Atherosclerotic plaque rupture, ulceration, fissuring, erosion or dissection with 
resulting intra luminal thrombus in one or more coronary arteries is included in Type1. 
 Type 2: myocardial infarction secondary to ischemic imbalance 
Myocardial injury caused by conditions other than CAD, leading to imbalance 
between myocardial oxygen supply and demand ex: coronary endothelial dysfunction, 
coronary artery spasm, embolism, anemia, arrhythmias etc. 
 Type 3: myocardial infarction resulting in death when biomarker values are 
available 
Cardiac death with symptoms suggestive of ischemia and presumed new ischemic 
ECG changes before blood samples could be collected. 
 Type 4a: myocardial infarction related to percutaneous coronary intervention 
It is arbitrarily defined as elevation of cTn values >5 *99
th
 percentile URL in patients 
with normal baseline values (<99
th
 percentile URL) or a rise of cTn values >20% if 
the baseline values s\are elevated and are stable or falling. In addition to this 1) 
symptoms suggestive of myocardial ischemia 2)new ischemic ECG changes 
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3)angiographic loss of patency of a major coronary artery or a side vessel or a 
4)imaging demonstration of new loss of viable myocardium or chest wall abnormality 
is required. 
 Type 4b: myocardial infarction related to stent thrombosis 
It is detected by coronary angiography or autopsy with a rise and/fall of cardiac 
biomarkers with at least one values above 99
th
 percentile. 
 Type 5: myocardial infarction related to coronary artery bypass grafting 
It is defined by elevated cardiac biomarkers >10* 99
th
 percentile URL. In addition- 
either 1) new pathological Q waves or new LBBB or 2) angiographically documented 
new graft or new native coronary artery occlusion or 3) imaging evidence of new loss 
of viable myocardium or new regional wall motion abnormality 
CLINICAL FEATURES 
Diaphoresis, nausea, and vomiting, cold peripheries, delirium, giddiness, abdominal 
discomfort, unexplained syncope attacks 
(8) 
 Symptoms 
Crushing pain lasting usually for 15m inutes or more with or without 
 Nausea , vomiting , abdominal blotting 
 Pallor 
 Sweating , fatigue 
 Feeling of  impending death 
 Breathing difficulty 
 
SIGNS:  
 Rapid thready (low volume) pulse  
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 Elevated blood pressure due to pain  
 Low blood pressure due to cardiogenic shock  
 Elevated jugular venous pulse  
 Peripheral and central cyanosis 
 Febrile because of ongoing inflammation  
 Tachypnoea in left ventricular dysfunction  
 Tachycardia or bradycardia ( inferior wall MI)  
 Lung crepitations in pulmonary edema  
 Muffled heart sounds especially S1  
 Systolic murmur due to ventricular septal rupture or papillary muscle rupture  
 
LABORATORY INVESTIGATIONS 
 
 CREATINE KINASE(CK) : 
Serum creatinine kinase peaks at approximately 24 hours. It starts to elevate within 
four to eight hours. However reperfusion either by fibrinolytic therapy or surgical 
recanalization can influence the enzyme values by influencing infarct size or time 
activity graph of the enzyme 
(13) 
CK-MB iso-enzyme immunoassay is highly sensitive and specific for ischemic heart 
disease .A ratio of 2.5 between  creatinine kinase MB and creatinine kinase is 
highly indicative for myocardial injury 
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 Troponins 
Troponins are proteins that help in muscle contractions , they are present in both 
skeletal and cardiac muscles. However the main acid sequences in the cardiac and 
skeletal troponins are different. Therefore quantitative assays using antibodies against 
cardiac troponins (c TnT and c TnI) can be used for the diagnosis of MI 
The levels of c Tnt & c TnI starts to rise by 3 hours of experiencing angina. The levels 
of c TnI and c TnT remain elevated for 7- 10 days and 10-14 days respectively. 
ADVANTAGES OF CARDIAC TROPONINS 
 Remain elevated for a long time ,thus helping in diagnosis in those 
presenting late 
 As an indicator of reperfusion – if reperfusion is successful ,there is a 
sudden release of large amount of cardiac troponins 
 Cardiac troponins can detect degrees of cardiac tissue necrosis which are 
below the range of creatinine kinase MB. 
Diagram no:10  Cardiac markers 
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Diagram no :11 graphical representation of rise and fall of cardiac biomarkers 
 
 
Emerging biomarkers 
Brain natriuretic peptide and N-terminal pro brain natriuretic peptide 
Like atrial natriuretic peptide, BNP is also secreted from the heart in response to 
stretch receptors within the muscle wall. Here BNP and Pro BNP have become well 
established biomarkers for left ventricular dysfunction. 
However, they are also being investigated as prognostic indicators of long term 
mortality early after an acute coronary event. This was applicable to entire spectrum 
of acute coronary syndrome, including STEMI, NSTEMI and unstable angina. A trend 
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towards favorable outcomes was seen in a sub study of FRISC II trial following an 
early invasive strategy in patients with high values of NT-Pro BNP. 
C-reactive protein 
C-reactive protein (CRP) is an acute phase reactant protein secreted by the liver in 
response to acute inflammatory conditions. Recent studies have compared the values 
of CRP and the other established biomarkers in patients with ACS.CRP can be used 
by the clinician when risk stratification with additional prognostic information is 
desired. 
Developing biomarkers 
The present biomarkers have ailed physicians in diagnosis and prognostication of 
ACS but there are areas where they are found to be deficient 
 Low sensitivity in the initial 4-6 hours after onset of chest pain. This issue is 
being addressed by ultrasensitive troponins now 
 In the absence of myocardial necrosis, they are poor markers for ischemia 
 They are affected by injury or inflammation of other body organs. 
A number of novel biomarkers re in the development stage in recent years. 
Myeloperoxidase  
MPO is a degranulation product coming from white cells. It may be involved in the 
development of lipid laden soft plaque, protease cascade activation and nitric oxide 
consumption. Thus MPO is an indicator of inflammation  and plaque instability ,but 
not ischemia. 
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In one study, MPO level was an independent prognostic factor for outcome at 6 
months in terms of death and recurrent MI. even though various studies have shown a 
positive correlation between MPO levels and a worse outcome, more studies are 
required to establish the efficacy of MPO in detecting mild ACS and adverse 
prognosis. 
Soluble CD40 ligand 
It is a signaling protein that reflects both inflammatory and platelet interactions within 
the plaque. 
Matrix metalloproteinases(MMP) 
These are a class of endopeptidases that are regulators of the extracellular matrix 
(ECM). MMP- 9 is localized in the shoulder of the plaque which is the thinnest 
portion of the plaque. Blackenburg et all examined the potential of MMP-9 in the risk 
stratification of people with ACS. Higher values were found to have a positive 
correlation with adverse myocardial events in the future. 
Fatty acid binding proteins 
They are the major vehicles for cytosolic transport of long chain unesterified fatty 
acids. Heart type fatty acid binding proteins (H-FABP) appears in the blood soon after 
MI (within 2-3hours) and returns to normal ( within 12-24hours) in patients without 
renal impairment. 
It has been suggested that FABP can be used in diagnosis of chest pain of uncertain 
origin and as a marker of ischemia when there is no myocardial necrosis. However 
lack of specificity, constraints its use. 
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Free fatty acids unbound to albumin 
It has been evaluated for early identification of cardiac ischemia. Several studies have 
implicated the sensitivity of this marker on admission to emergency room and have 
shown that free fatty acids unbound too albumin evaluated earlier than the traditional 
biomarkers in 100% of the patients. 
Ischemia modified albumin 
Levels of Ischemia modified albumin (IMA) holds a strong negative predictive value 
for ischemia even prior to necrosis. This is based on the theory that metal binding sites 
on albumin are altered on exposure to ischemia. When combined with cardiac 
Troponin T and ECG, IMA is extremely useful to rule out ACS. However due to the 
lack of a gold standard to evaluate non necrotic ischemia, it has been difficult to assess 
IMA  
Pregnancy associated plasma protein 3 
This is a member of insulin like growth factor family of proteins and is considered to 
be elevated in neo-vascularisation. This PAPP-A protein may be used as a marker for 
impending plaque rupture. 
Placental growth factor 
It is a member of vascular endothelial growth factor (VEGF) and was shown to be 
elevated in early and late atherosclerotic plaque. Placental growth factor (PIGF) is 
mainly involved in the inflammatory process of atherosclerosis. However like PAPP-
A , no standard assays are available to assess the efficacy of these markers. 
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MYOGLOBIN 
The levels of myoglobin are elevated before CK-MB and cardiac troponins. However 
due to its lack of cardiac specificity, myoglobin values alone are not sufficient in 
making a diagnosis of MI 
SERUM LIPIDS 
A lipid profile should be obtained in all patients who are admitted within 24- 48 hours 
of symptoms. This can help in risk assessment. However, their values start to fall after 
24 -48 hours; the fall in HDL value is greater than the fall in cholesterol. So the ratio 
of HDL to cholesterol cannot be taken for risk assessment if measured late. 
HEMATOLOGICAL FINDINGS 
Leukocytosis occurs within two hours of developing symptoms. ESR starts to rise 
usually 1 or 2 days after the onset of symptoms and remain elevated for several weeks. 
It is unrelated to the prognosis and size of infarct 
 
ELECTROCARDIOGRAM 
Diagram no: 12 ECG changes in MI over a period of time 
 
ECG is a basic diagnostic modality in the treatment of MI. 
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For the diagnosis of STEMI, an elevation of 1mm or more in ST segments of two or 
more contiguous leads is necessary. A reciprocal change (ST depression) in leads 
leading away from the site of infarct further confirms the diagnosis. 
(9)
 
 ECG Changes  
INFERIOR WALL MI– elevation in LEAD II and LEAD III with ST depression in 
lead I, avl or both. 
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Diagram no: 13  
 
 
 
Patients with NSTEMI can present with marked or minimal ST-segment depression or 
isolated T wave changes. This identifies patients at higher risk who subsequently benefit 
most from an aggressive management strategy 
(10). 
 
Echocardiography 
 Abnormal wall motility is seen in all patents with MI and the degree of   abnormality 
can be  categorized with  wall motion .An echocardiogram can help in assessment of 
risk , diagnosis in patients with symptoms suggestive of MI but normal to near normal 
ECG and the risk of developing congestive cardiac failure. 
(14) 
Chest X ray 
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It helps in ruling out other diseases like aortic dissection which can mimic MI. It also 
helps to rule out pulmonary oedema which can develop as a result of systolic or 
diastolic dysfunction 
(12) 
RADIONUCLIDE TECHNIQUE  
It can detect infarction earlier than enzyme. This test is not generally used as it is 
expensive and cannot distinguish between a new infarct and an old scar. 
POSITRON EMISSION TOMOGRAPHY  
PET can easily differentiate stunned myocardium due to acute ischemia from an old 
scar .18 fluoro-deoxy glucose is used as a marter. PET uses positron emitting agents to 
demonstrate change in metabolism of the cardiac tissues. 
 
CORONARY ARTERIOGRAPHY  
It is indicated in 
 Patients with persisting symptoms; unconfirmed diagnosis of MI  
 chronic stable angina in spite of medical therapy 
 angina patients who suffered cardiac arrest and survived 
 patients with clinical or laboratory evidence of ventricular dysfunction (16) 
Non invasive options include CT angiography and MR angiography. The high dose 
radiation of CT angiography and cardiac motion induced artifacts on MR angiography 
are the main limitations. 
STRESS TESTING 
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One day prior to the test all medications including beta blockers are discontinued. A 
12lead ECG is taken while the patient is made to exercise upto 85% of predicted heart 
rate. The endpoints are inability to exercise for more than 2min, a new ST depression 
of 2mm or more or development of heart failure, hypotension or arrhythmia. 
Drugs like adenosine, dypiridamole and dobutamine can also be used instead of 
exercise
. (15)
 
RISK STRATIFICATION AND PROGNOSIS:  
Thrombolysis in MI Risk Score for Unstable Angina/NSTEMI  
One Point score for each of 
the Following:  
 Score   Risk of Adverse Event[*]    
 Age ≥65 years   0/1   4.7%    
 Presence of =3 CV risk 
factors  
 2   8.3%    
 Recent (<24 h) severe angina   3   13.2%    
 Known coronary stenosis 
≥50%  
 4   19.9%    
 ST-segment deviation on 
admission ECG ≥0.5 mm  
 5   26.2%   
 
 
Thrombolysis in MI Score for STEMI  
 
Various Risk Factors   Points   Total Score   30-Day Mortality 
rate (%)  
  
 Patient Age ≥75 years   3   0   0.8    
 Patient Age 65-74 
years  
 2   1   1.6    
 Systolic Blood Pressure 
<100 mm Hg  
 3   2   2.2    
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 Pulse rate>100 
beats/min  
 2   3   4.4    
 Killip class more than 1   2   4   7.3    
 Anterior MI or LBBB   1   5   12.4   
 
Abbreviations: BP = blood pressure; HTN =hypertension; LBBB = left bundle branch block; 
MI = myocardial infarction  
 
   
  COMPLICATIONS OF MI 
 Pericarditis 
 Cardiac tamponade 
 Arrhythmias 
 Cardiogenic shock 
 Congestive heart failure 
 Stroke 
Diagram no: 13 summary of complications of MI 
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MANAGEMENT 
Basic steps include – 
 Establishing an IV access and stabilising the patients 
 Drug therapy include  
 Control of pain by sublingual nitrates, nitroglycerin or IV morphine 
Nitroglycerin it can be given as a sublingual or intravenous dose. It helps in 
alleviating pain. It causes coronary vasodilatation and decrease in venous preload. 
However it should preferably not used in patients with inferior wall and right 
ventricular MI. it is contraindicated in patients with hypotension and those who have 
used PDE inhibitors within 24 hours 
Intravenous Morphine of 2-4mg: it reduces pain, decreases myocardial oxygen 
demand, reduction in sympathetic tone and alleviates anxiety of the patient 
 
 Minimize  myocardial oxygen demand 
Beta blockers reduce pain, reduce oxygen mismatch by reducing heart rate, decrease 
the chance of developing arrhythmias and even decrease infarct size .Oral beta blocker 
therapy should be started in all patients in the absence of contraindications. 
Metaprolol is used because of its short half life 
 Intravenous beta blockers are used in acute AC after excluding patients in heart 
failure, hypotension (< 90mm Hg), bradycardia (<60 bpm) or heart block 
 Maintain myocardial perfusion  
Aspirin  
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It is an irreversible cyclo-oxygenase inhibitor. All patients with MI should receive a 
loading dose of 300mg followed by 150 mg .it reduces mortality in patients with ACS 
Clopidogrel 
It is an anti-platelet drug. Combined with aspirin it reduces the incidence of re 
infarction, stroke and cardiovascular death 
Heparin 
It acts by activating anti thrombin III, inhibits thrombin and factor IX a. In patients 
with ACS 70IU/kg bolus IV followed by an infusion rate 12-15 IU/kg/Hour infusion 
rate is maintained
. (17) 
Reperfusion therapy 
 A 12 lead ECG is the primary tool in the diagnosis of acute coronary syndrome. The 
time from symptom onset to reperfusion is the most important determinant in the 
latter’s success, whatever the modality of reperfusion may be. 
In the absence of ST elevation, thrombolysis is ineffectual and can be harmful. If the 
patient presents within 3 hours of onset of symptom and there is no delay in invasive 
strategy, either strategy can be tried 
 Fibrinolysis 
It is preferred when presentation is within 3 hours and PCI is not a preferable option 
due to difficulty in vascular access, delay in transportation and lack of catheterization 
facilities. 
The agents used are streptokinase, alteplase etc 
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Contraindications and Cautions for Thrombolysis in STEMI 
(19)
: 
 
 
 
 
 
 
 
 
Relative contraindications: 
 History of ICH 
 Ischemic stroke within 3 months 
 Suspected aortic dissection 
 Active bleeding or bleeding 
diathesis (excluding menses) 
 Intracranial neoplasm or vascular 
anomaly 
 Head or facial injury in the last 3 
months 
 severe hypertension ( >180/110 mm hg) 
 History of ischemic stroke >3 months 
 Recent (within 2-4 wk) internal bleeding 
 Pregnancy 
 Active peptic ulcer 
 Current use of anticoagulants INR > 2.0 
 Major internal surgery within3 weeks 
 Prior streptokinase exposure 
 CPR for greater than 10 min 
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Percutaneous coronary intervention 
.  
It is the treatment modality of choice in patients with contraindications for 
thrombolysis. It is the preferred mode in patients in cardiogenic shock as it carries a 
lower risk for hemorrhagic complications 
(20) 
PCI is chosen when 
High risk from STEMI 
- Cardiogenic shock 
- Killip class ≥3 
- Contraindications to fibrinolysis including increased risk of bleeding, ICH 
-Late presentation 
- Symptom onset was more than 3 hr ago 
-Diagnosis of STEMI is in doubt. 
FEMALE RELATED STATISTICS 
 
HYPERTENSION: 
Framingham data revealed that women with systolic blood pressure greater than 180 
had an annual incidence of coronary events > 30% while in men it is >50%. 
The probability of developing hypertension increase with advancing age, since women 
have a longer life expectancy than men, there are more elderly women with 
hypertension 
(23) 
Diastolic blood pressure also is an important predictor of ACS as predicted by other 
clinical studies. 
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The pharmacotherapeutic and pharmacodynamic properties of ACE inhibitors and 
thiazide diuretics in relation to gender is under study. The common side effects of 
ACE inhibitors like cough are more common in females than males. 
(30)
 It is important 
to note that ACE inhibitors have teratogenic potential and are contraindicated in 
pregnant women especially in the first and second trimester. 
(29)
 
Thiazide diuretics have been proven to be beneficial in menopausal women due to its 
effect on bone mineral density. Studies have shown that it decreases the incidence of 
hip fractures by approximately one third
. (24) 
LIPIDS  
An abnormal lipid profile is an important tool in the risk estimation of both men and 
women. The lipid profile of both sexes is different and also varies in their impact on 
cardiovascular events.
 (31)
 
 The co-relation between low HDL and cardiovascular events is more significant in 
women than males compared to other lipoprotein components; HDL values are more 
predictive for females. 
 The pharmacologic control of hyperlipidemia after an episode of MI has been proven 
to be beneficial in both sexes. However, it is observed that the dosage of Hmg CoA 
inhibitors used in women is often inadequate and target levels are not reached. The 
recent cholesterol control guidelines recommend aggressive primary prevention of 
hypercholesterolemia in diabetic females. 
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DIABETES 
 Even though mortality rates after ACS have generally been declining in the past 
decade, mortality rates in diabetic women with ACS have increased by 23 percent 
while it has decreased by 27 percent in non diabetic females. It is quite clear that 
diabetes predisposes to serious complications after MI and mortality
. (21)
 
 Higher in-hospital mortality and congestive heart failure is seen among women than 
men. The presence of hypertension in diabetic patients both male and female further 
increases the mortality rates. 
(34)
 
Diabetes confers substantially increased relative risk of first incident and admission 
for MI in women above 65 years of age compared with age to sex matched controls 
younger than age 65 years over 20 years follow up in Copenhagen City heart Study 
(35).
 
Altered lipid profile is highly common in diabetic patients. A low level of HDL 
correlating with increased incidence of coronary events is more common in diabetic 
females. Other lipoprotein components are also elevated. Use of HMG Co A 
Inhibitors for hyperlipidemia in diabetic patients has resulted in fewer incidence of 
coronary vascular event. 
 Gestational diabetes and obesity predisposes to the development of diabetes. The 
possibility of developing diabetes can be attenuated by even a moderate increase in 
physical exertion and weight reduction
. (37)
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INSULIN RESISTANCE SYNDROMES  
 
The insulin resistance condition comprises a spectrum of disorders, with 
hyperglycemia representing one of the most readily diagnosed features. The metabolic 
syndrome, the insulin resistance syndrome, or syndrome X are terms used to describe a 
constellation of metabolic derangements that includes insulin resistance, hypertension, 
dyslipidemia (decreased HDL and elevated triglycerides), central or visceral obesity, 
type 2 diabetes or IGT/IFG, and accelerated cardiovascular disease
(41).
  
Mutations in the insulin receptor that interfere with binding or signal transduction are 
a rare cause of insulin resistance. Acanthosis nigricans and signs of hyperandrogenism 
(hirsutism, acne, and oligomenorrhea in women) are also common physical features. 
Two distinct syndromes of severe insulin resistance have been described in adults: (1) 
type A, which affects young women and is characterized by severe hyperinsulinemia, 
obesity, and features of hyperandrogenism; and (2) type B, which affects middle-aged 
women and is characterized by severe hyperinsulinemia, features of 
hyperandrogenism, and autoimmune disorders. Individuals with the type A insulin 
resistance syndrome have an undefined defect in the insulin-signaling pathway; 
individuals with the type B insulin resistance syndrome have autoantibodies directed 
at the insulin receptor.  
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These receptor autoantibodies may block insulin binding or may stimulate the insulin 
receptor, leading to intermittent hypoglycemia.  
 
Polycystic ovary syndrome (PCOS) is a common disorder that affects premenopausal 
women and is characterized by chronic anovulation and hyperandrogenism. Insulin 
resistance is seen in a significant subset of women with PCOS, and the disorder 
substantially increases the risk for type 2 DM, independent of the effects of obesity.  
 
 
HYPERGLYCEMIA IN MYOCARDIAL INFARCTION:  
The mortality and morbidity of the diabetic patient sustaining a myocardial infarction 
is poor compared with that of non-diabetic patients. Studies have shown that 
hyperglycemia induces adverse prognosis even in non diabetic patients. Claure 
Bennard observed and explained acute hyperglycemic response to stress more than a 
century ago. “Diabetes of injury” concept evolved as glucose has been identified as 
metabolic mirror of the severity and outcome of critical illness.  
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OBESITY  
The prevalence of obesity is on the rise in our country. This can be attributed to the 
hazardous change in diet and lifestyle of the people. 
 Obesity is one of the most important modifiable risk factor in the development of 
ACS. Along with this, it is related to the other cardiac risk factors like diabetes, 
hyperlipidemia, and metabolic syndrome
. (39)
 An increased waist circumference has 
comparatively more impact than a raised BMI. 
(41)
 The type of weight distribution also 
influences the risk, i.e. apple shaped abdomen is more dangerous than pear shaped 
abdomen. 
Diagram no: 13 
 
 
Even though many revolutionary drugs have come into the market for the treatment of 
obesity, the adverse effects often outweigh the benefits. 
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PHYSICAL ACTIVITY AND EXERCISE: 
Exercise and physical activity is important for both primary and secondary prevention 
of vascular events. 
(47)
 Studies have proven that women who walk for 1 hour each 
week have lesser incidence of cardiac events than women who d not walk regularly. 
However, studies on the influence of exercise usually focus on leisure activities like 
yoga aerobic etc and exclude household work and child care. This can lead to 
underestimating the actual energy expenditure of women. 
 
MENOPAUSE AND HORMONAL THERAPY 
The effect of menopause and hormonal therapy on cardiovascular events is still under 
study. Coronary artery disease is the leading cause of death in post menopausal 
women. Gynaecological surveys have shown an increased risk of developing ACS in 
women with early menopause due to reduced hormone exposure 
The Women’s Health Initiative (WHI) study investigated health risks and benefits of 
hormonal therapy in healthy menopausal women aged 50 – 79 years old. (49) In the 
study 
 Continuous combined HRT (CEE 0.625 mg + MPA 2.5 mg) was given to 
women with intact uterus. The study which was originally supposed to run for 
8.5 years was stopped after 5.2years because the harm (CHD , stroke, 
pulmonary embolism) outweighed benefit 
 Oestrogen alone was given to women with previous hysterectomy. This study 
was also discontinued due to no heart disease benefit and increased stroke risk.  
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The HERS study (Heart and oestrogen progestin replacement study) conducted earlier 
was the first secondary prevention clinical trial which demonstrated that hormone 
replacement therapy showed no benefit in the prevention of coronary heart disease. 
These postmenopausal women had an incidence of coronary artery disease 
(myocardial infarction, coronary artery bypass grafting, percutaneous transluminal 
coronary angioplasty for occlusion >50 percent, or angiography with more than one 
major coronary artery) 
Based on the above studies, national guidelines have stressed the importance of other 
modalities of prevention over hormone replacement. In counselling post menopausal 
women, cardiovascular prevention should be given importance. 
PSYCHOSOCIAL FACTORS 
Emotional stress plays an important role in predisposing an individual to CAD as well 
as in increasing morbidity and mortality after a cardiovascular event. The Nurses’ 
health study has revealed that sudden cardiac death is associated with phobic anxiety 
which is more common in women. Acute and reversible cardiomyopathy following 
stress has also been proven
.(50)
 Women with lower socioeconomic status has a higher 
probability of developing CHD and higher mortality which is often due to the delay in 
treatment and improper understanding of the severity of the disease. 
Women are more prone to develop depression than men. Interestingly, news of cancer 
is less likely to cause depressive feelings than a myocardial infarction. Depression is 
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more likely to develop in young women with co-morbidities and low socio economic 
status, evidenced by Prospective Registry 
Evaluation Outcomes after Myocardial Infarction: Events and Recovery 
(PREMIER) study. Women diagnosed with depression are generally undertreated. 
TOBACCO 
Irrespective of age and gender, tobacco exposure is an important risk factor in the 
development of CAD. It is important to note that incidence of CHD increases 
proportionally with the amount and duration of smoking in a dose related fashion. 
In women, smoking leads to earlier onset of menopause and MI. the danger of 
smoking becomes clear when it is contemplated that women are the usual candidates 
for asymptomatic MI. 
Potential weight gain on cessation of smoking is an important discouraging factor for 
women. However many interventions have been developed which can help with this 
problem. This includes proper counselling, physical activity and pharmacotherapy. 
Increase in physical activity itself helps in quitting smoking. 
Pharmacological approach includes nicotine replacement and bupropion. Nicotine 
replacement increases the chance for success in smoking cessation. bupropion has an 
antidepressant action; it helps in cessation of smoking and has been found to be 
beneficial in minimizing weight gain. It should be avoided in patients with history 
suggestive of anorexia/ bulimia, heavy alcohol consumption, seizures and head trauma 
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RACIAL AND ETHNIC FACTORS 
The importance of racial, social and ethnic factors in the development of 
cardiovascular diseases has recently come into the limelight. According to the 1986 
National Mortality Feedback Survey, the 1985 National Health Interview Survey, and 
the U.S .Bureau of the Census Black women aged less than 55 years have a higher 
cardiovascular mortality than young American women and young men. 
The data on Asian women and those living in India is insufficient, however the recent 
years have shown an increase in the number of young women and men presenting 
with MI 
SIGNIFICANT COMORBIDITIES 
Higher risk of coronary artery diseases is seen in patients with inflammation of 
coronary vasculature. 
The potential of SLE and rheumatoid arthritis to act as an etiological factor in CAD 
has been highlighted 
SLE (systemic lupus erythrematosus): 
There is five-fold increased risk for developing CAD in patients with SLE. 
Cardiac ultrasound done on 197 SLE patients and matched controls showed 
That 37.1 percent of SLE patient had cardiac plaques. Those with cardiac plaques had 
a longer duration of SLE, generally older than 40, with inadequate treatment with anti 
inflammatory drugs. 
. 
Rheumatoid arthritis: 
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Rheumatoid arthritis increases the mortality and morbidity in cardiovascular events. 
98 women with rheumatoid arthritis were assessed with cardiac ultrasound for the 
evidence of atherosclerosis. 44 percent of these women showed the presence of 
plaques as compared to 15 percent age matched hypertensive women. Anti-
inflammatory drugs like methotrexate have been shown to reduce cardiovascular 
mortality in rheumatoid arthritis. 
INTERVENTIONS FOR CORONARY ARTERY DISEASE: 
According to the recent statistics, 33 percent of patients treated with PCI are women. 
Complications both short and long term are more common in females than males. this 
might be related to the higher incidence of co morbidities, longer duration of 
symptoms and older age in females. Vascular complications are also more prevalent in 
females
. (51)
 The advent of smaller coronary catheters has slightly decreased the gender 
specific variations in complications. 
 Statistically, men underwent CABG more commonly than women. 
(51)
 Experiments 
have shown that women with off-pump CABG were having older age and smaller 
surface area. Despite controlling these factors and other co morbidities women 
showed higher incidence of wound infections and longer in-patient stay   but 
decreased mortality. 
SUDDEN DEATH 
Phobic anxiety which is more common in women than men increases the risk of fatal 
complications of CHD and sudden death. The Nurses’ health study found that phobic 
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anxiety correlated with smoking, diabetes, hypertension, hyperlipidemia and 
BMI>30kg/m2
. (52)
 
Arrhythmias 
 Women respond to the need in increasing cardiac output during physical exercise by 
increasing heart rate
.(53)
 Women have a higher heart rate than men and studies have 
shown that after excluding potential confounders like diabetes, hypertension, previous 
CHD , anaemia and smoking, women with HR >60 bpm have higher cardiovascular 
mortality rates 
 The type of arrhythmia predominant in males and females varies. Men are prone to 
develop atrial and ventricular fibrillation related with WPW syndrome, while women 
are more prone to develop atrio-ventricular node re-entrant tachycardia and 
orthodromic supraventricular tachycardia. 
Drug-induced torsade de pointes occurs more commonly in women than men and the 
former  have a higher risk of dying of atrial fibrillation. 
 In an important randomized control study done in women with atrial fibrillation, rate 
control has shown to be more beneficial than rhythm control despite prior electrical 
cardioversion. 
DIAGNOSIS OF CAD IN WOMEN 
Further evaluation is necessary after establishing a diagnosis a coronary artery disease. 
The earliest known non invasive technique of exercise stress testing shows low 
specificity and sensitivity for women. 
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Severity of coronary heart disease can be assessed in women with stress imaging 
techniques. Breast tissue can cause soft tissue attenuation in nuclear stress perfusion 
using thallium, so technetium is used. 
Cardiac catheterization is less likely to show CAD in women so stress imaging 
techniques are usually preferred. 
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UNSTABLE ANGINA AND NON-ST SEGMENT ELEVATION MI 
Definition 
Stable angina is defined as chest or arm discomfort precipitated by emotional stress or 
exercise it is relieved within 15minuts by rest or sublingual nitroglycerin. Unstable   
angina has at least one of the three features. 
 Occurring at rest and lasting >20 minutes 
 Crescendo angina 
Classification 
The branwald clinical classification gives three groups 
 A – primary angina 
 B – secondary angina 
 C-post mi unstable angina 
 Class1angina-new onset of severe angina or accelerated angina no rest pain 
 Class2-angina at rest with in the past month but not within 48 hours 
 Class3 –angina at rest within 48 hours 
Classification according to aetiology 
 Plaque rupture and erosion 
Rupture usually takes place at the shoulder region of the plaque because this area is 
infiltrated with inflammatory cells and subjected to high shear forces. High risk 
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plaques have thin fibrous cap and large lipid pool which increases the chance for 
rupture. In contrast fibrosis and calcification attenuates the risk for rupture
. (6) 
Erosion occurs centrally rather than at the shoulder.  It appears to be more common 
among women who smoke whereas these plaque rupture occurs in hyperlipidemic 
men. 
 Inflammation 
It plays the most important role in plaque disruption. The monocytes, leucocytes and 
the endothelial cells in the plaque express adherent molecules which lead to 
accumulation of macrophages and T-lymphocytes. There is cytokines and chemokines 
as well as which degrades collagen that provides strength of the fibrous cap. 
(7) 
 Infection 
CMV, helicobacter pylori and Chlamydia pneumonia have been identified within 
atherosclerotic plaques. Also antibodies against Chlamydia heat shock proteins cross 
reacts with heat shock proteins produced by endothelium. However antibiotics 
regimens against Chlamydia have not shown any conclusive benefit. 
 Platelet aggression 
Platelets play a key role in the formation of unstable lesion from a stable 
atherosclerotic plaque there are three major steps in this process adhesion, activation, 
aggregation. 
(4)
 When a atherosclerotic plaque disrupts the collagen and tissue factor is 
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exposed to circulating blood and this leads to platelet adhesion via the platelet Gp1b 
receptor following its interaction with von willebrand factor and gpv1 binding to 
collagen. 
The next step is platelet activation which consists of change in shape of the platelets, 
realise of platelet contents including thromboxine A2 and activation of gp2b/3a on 
their surface the next step is platelet aggregation in which cross linking of the platelet 
by fibrinogen occurs. 
 Clotting cascade 
After plaque rupture haemostasis is attained by the release of tissue factor. Thrombin 
is generated by the activation of factor X to Xa, this thrombin will convert fibrinogen 
in to fibrin activating factor XIII which stabilizes the fibrin coat leading to further 
propagation of the thrombosis. 
(4) 
 Thrombosis 
It has a great role play in the pathophysiology of  UA/NSTEMI 
 Coronary vasoconstriction 
In contrast to the coronary artery segments of culprit lesion of patients with stable 
angina, culprit lesion in UA/NSTEMI have an increased response to vasoconstrictor 
stimuli. In prinzmetals variant angina focal spasm of a segment of epicardial coronary 
arteries are seen. The role of coronary vasoconstriction causing micro circulatory 
 
 
 
 
60 
 
angina resulting from constriction of small intramural coronary resistant vessel is 
evident 
Secondary unstable angina 
It occurs due to imbalance between oxygen supply and demand which is precipitated 
by condition like fever thyrotoxicosis , hypertension and aortic stenosis. 
 Progressive mechanical obstruction 
Unstable angina/NSTEMI can be caused by progressive luminal narrowing of the 
coronary arteries. This condition is usually seen in restenosis following PCI. However 
this can also occur without PCI and it is related to rapid cellular proliferation 
Diagnostic tools 
Other than history and clinical examination the following modalities are used. 
 Electrocardiogram 
It is the most important diagnostic tool in the evaluation of a patient with suspected 
NSTEMI ACS. 
(2)
 ECG helps in the diagnosis and also in the risk stratification based 
on pattern and magnitude of abnormalities. In UA, ST depression is transient and ST 
elevation and/or T wave inversion occurs in 30-60% of patients depending on the 
severity. Several studies have shown that new ST segment deviation even if only 0.05 
mv is specific and an important measure of ischemia and prognosis. ST depression of 
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1mm is associated with 11% mortality and ST depression of >2 mm is indicative of 6 
fold increased mortality 
 Continuous ECG monitoring 
About two thirds of all ischemic episodes, especially in the initial hours are clinically 
silent and thus not likely to be seen in a conventional ECG. Continuous computerised 
12 leads ST segment monitoring is an important diagnostic tool 
 Exercise or other stress test 
In a patient with typical chest pain no stress test should be done in acute phase. 
However in a patient with inconclusive ECG, stress test has a better predictive value. 
A negative exercise testing has a high negative predictive value. 
 Echocardiogram 
It can detect transient localised abnormal wall motility during ischemia, it also helps 
in exclusion of aortic stenosis, aortic dissection, embolism or HOCM. Echo 
cardiography can also assess the LV systolic function which is an important 
prognostic marker in patients with IHD. 
 Biochemical markers 
The elevation of biomarkers like CK-MB, troponin T and I identifies patients 
with NSTEMI. Patients with negative cardiac biomarkers with symptoms 
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highly suggestive of ACS should have biomarkers re-measured in the time 
frame 8 to 12 hours after the symptom onset. 
 Imaging of coronary anatomy 
The gold standard is invasive coronary angiography if revascularisation is considered 
it is absolutely essential to have angiographic imaging of coronary blood vessel. 
(2)
CT 
angiography cannot be recommended as the coronary imaging modality of choice at 
present 
 Other laboratory tests 
Chest x ray is performed in the admission to rule out pulmonary congestion. Serum 
cholesterol value should be measured at the time of presentation they begin to fall by 
30-40% within 24 hours of ACS. 
The Newer anti-platelet drugs 
 Prasugrel 
It provides more profound and faster antiplatelet action than clopidogrel. However 
there was increased incidence of bleeding. Excess bleeding with prasugrel was not 
seen in diabetic patients since their platelets are known to be more hyper active 
 Ticagrelor/azd6140 
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It is a reversible inhibitor of p2y12 receptor with half life of 12 hours. As compared to 
clopidogrel it reduces vascular death, non fatal MI or non fatal stroke. The use of this 
agent as associated with dyspnoea and ventricular pauses 
 Cangrelor 
It is a reversible potent short acting intravenous p2y12 receptor inhibitor with rapid 
onset of action. In the most recent CHAMPION PHOENIX trial cangrelor reduced the 
rate of ischemic events including stent thrombosis during PCI. It was not associated 
with increased bleeding complications. 
 Thrombin receptor antagonists 
It blocks platelet protease activated receptor. Ongoing TRA programs have shown a 
major decrease in cardiovascular events without any increase in bleeding. 
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MATERIALS AND METHODS 
 
This study was conducted at Thanjavur medical college during the time period 
December 2014 to may 2015 
 It is a cross sectional study 
Source of data: 
Consecutive cases of female patients admitted in the medicine casualty of Thanjavur 
medical college & hospital, who satisfied the inclusion criteria. 
 
Sample size: 50 
 Inclusion criteria: 
 ACS in female patients diagnosed by 
 Symptoms s/o ACS  with definite ECG changes 
 Or raised cardiac markers 
Exclusion criteria: 
 Chest pain with normal ECG and normal cardiac markers. 
 50 female patients who presented with symptoms s/o ACS with ECG changes 
and/or raised cardiac markers were studied with detailed history with special regard 
to history risk analysis. 
Investigations:  
CBC, RBS, RFT, fasting lipid profile, ECG, Troponin T and echocardiogram were 
done for these patients. 
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 Hypertension was documented either by history of hypertension or by a 
measurement value of > 140/90 mm Hg. 
 Diabetes was documented either by history or a RBS value > 200 Mg/dl with 
importance given to the duration of diabetes and treatment 
 Clinical symptoms at the time of presentation like chest pain, epigastric pain, 
palpitation and other symptoms were taken into account and patient stratification 
was done accordingly. 
 Physical signs like hypotension, raised JVP, s3, s4 and rales were considered and 
used for classifying patients. 
Patient stratification: 
 According to age, patients were classified into 4 groups : <45, 45-60, 60- 75 
and >75years. 
 With regard to diabetes, patients were classified into non diabetic, diabetic 
onset <10 years and diabetic onset >10 years. 
 Patients were also classified into hypertensive and non hypertensive. 
 Lifestyle factors were also given importance. Based on occupation, these 
patients were classified into 3 activity levels as sedentary, moderate and heavy 
workers 
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 Lifestyle modifications among the 50 patients were also assessed and they were 
classified as regular exercise, irregular exercise, dietary planning and no 
lifestyle modifications 
 Killip score is calculated based on classification according to the status of 
cardiac pump function, estimated clinically. 
 
 
 
Class I – No signs of pulmonary congestion or shock 
Class II – Moderate heart failure as evident by rales at the lung bases, S3 
Gallop, tachypnoea 
Class III- Severe heart failure (pulmonary oedema) 
Class IV- Cardiogenic shock with systolic BP < 90 mmHg, peripheral 
Vasoconstriction, cyanosis, oliguria and confusion 
ACTIVITY 
sedentary moderate heavy 
Teachers, 
executives, tailors, 
pharmacists 
Nurse,maids,cooli,basket 
makers,weaver,agricultural 
laborer ,beedi maker 
Mineworker, wood 
cutter 
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 Patients were classified into STEMI, NSTEMI and unstable angina with the 
help of ECG and cardiac markers and the type of MI was determined according 
to surface ECG. 
 
 
 
 Fasting lipid profile was done for these patients and HDL was classified into < 
or equal to 20, 20 -30, 30 – 40, 40- 50 and >50 mg/dl. LDL values were 
classified into <130, 130- 160, >160 mg/dl. 
 
 BMI was calculated by dividing weight in kg by height in metre square and it 
was classified into underweight, normal, over weight and obesity  
Class I, II AND III. 
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 Statistical  methods : 
1. Diagrammatic (bar / pie chart) representation  
2. Prevalence of risk factors and comparisons 
3. Mean and standard deviation 
 
 Study end point 
The primary aim of the study is identifying the prevalent risk factors in the study 
population 
 
LIMITATIONS 
 
 It is hospital based one step study. 
 Limited numbers of cases were studied. 
 Patients were not followed up for future complications after discharge from the 
hospital. 
 Limited number of risk factors were include in the study 
 Physical exercise did into take into account energy expenditure in household 
activities and child rearing 
 
 
 
 
69 
 
 Important risk factors like SLE, RA, and thyroid disorders were not tested, only 
history was taken into account. 
 Being a cross sectional study p value and risk ratio cannot be calculated. 
 
However, the study can serve as a base for understanding the prevalent risk 
factors in women with CAD and the prime importance of implementing 
primordial prevention in the community. 
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OBSERVATIONS 
 
CLINICAL PRESENTATIONS 
Table no: 1  
SYMPTOMS NO. OF PATIENTS (TOTAL n= 50) 
CHEST PAIN 39 
RADIATION 12 
BREATHLESSNESS 20 
NO CHEST PAIN 11 
EPIGASTRIC PAIN 10 
NAUSEA 9 
VOMITING 10 
PALPITATIONS 10 
 
OUT OF 50 PATIENTS ADMITTED WITH ACS, 78% of the patients presented with 
chest pain. Only 30.7% of those presenting with chest pain gave a typical history of 
squeezing or compressing chest pain with characteristic radiation. 
22 % of the study group did not complain of chest pain. 
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Table no 2: age wise distribution of patients without chest pain 
 
AGE( in yrs) 
NO OF PATIENTS 
(n=11) 
<45 0 
45-60 3 
60-75 4 
>75 4 
 
Out of the 11 patients without chest pain, 72.7% were above the age of 60 years 
Table no 3: prevalence of diabetes in patients without chest pain 
NO OF DIABETICS WITHOUT CHEST 
PAIN 
9 
NO OF NON DIABETICS WITHOUT 
CHEST PAIN 
2 
 TOTAL(n =11) 11 
 
Out of the 11patients, 82% were diabetics 
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Figure no: 1 
 
SIGNS 
Table no 4: prevalence of signs 
SIGNS No of Patients (TOTAL=50) 
CREPS/ BASAL CRACKLES 15 
S3 6 
S4 0 
JVP 5 
HYPOTENSION 4 
HYPERTENSION 5 
PUL.EDEMA/EXTENSIVE CRACKLES 11 
The most common sign presented by this group of 50 patients was basal crackles/  
 crepitations i.e. 30% 
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Figure no 2 
 
HISTORY 
Age wise distribution of patients with ACS 
Table no 5 
Age classification No of patients (total=50) 
<45yrs 2 (4%) 
45-60yrs 27 (54%) 
60-75 yrs 17 (34%) 
>75yr 4 (8%) 
 
Out of 50 patients, 54% belonged to the age group of 45-60 years. 
Basal crackle 
34% 
Pulm.edema 
22% 
S3 
13% 
JVP 
11% 
HYPOTENSION 
9% 
HYPERTENSION 
11% Prevalence of signs 
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Figure no 3 Frequency polygon of age wise distribution of ACS in females 
 
 
 
 
 
 
 
 
HISTORY OF DIABETES  
Table no 6 
Non diabetic 34(68%) 
No of diabetics ( >10years) 14(28%) 
No of diabetics (<10years) 2 (4%) 
Total  16(32%) 
In our cross sectional study 32% of the population was found to have diabetes. 
HYPERTENSION 
Table no 7 
 No of normotensives 25 
No of hypertensives 25(50%) 
Total (n = 50)  
0 
5 
10 
15 
20 
25 
30 
N
O
 O
F 
P
A
TI
EN
TS
 
AGE IN YEARS 
 
 
 
 
75 
 
50% of the patients in the study population were diagnosed as hypertensives. 
ROLE OF HORMONES 
 Out of 50 female ACS patients, only 6 were in the premenopausal age. 
44 of the patients had attained menopause. 
I.e., 88 % of the study group had attained menopause. 
 Oral contraceptive pills 
Out of 50 female patients, 8 (16%) gave a positive history of use of oral contraceptive 
pills on a regular basis. 
LIFESTYLE RISKS 
 Smoking and alcoholism 
Only 2 among the 50 female patients gave a positive history of smoking, 7 gave a 
history of tobacco chewing and 1 out of 50 gave a history of alcohol intake. 
I.e., 18% (2 +7) gave a history of tobacco use 
 occupation 
Classification of activities according to occupation 
Table no 8 
Activity No of patients (n=50) 
sedentary 25(50%) 
moderate 22 (44%) 
heavy 3(6%) 
 
50 % of the female patients in our study group led a sedentary lifestyle. 
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Classification based on lifestyle modifications 
Table no 9 
Lifestyle No of patients ( n=50) 
Dietary planning 2(4 %) 
Regular exercise 3(6%) 
Irregular exercise 4 (8%) 
No lifestyle modifications 41 (82%) 
 
41 of the 50 female patients did not practice regular exercise nor any dietary planning 
PAST HISTORY 
Table no 10 
HISTORY OF TIA/STROKE   4(8%) 
HISTORY OF IHD 7(14%) 
HISTORY OF RHD/SLE NIL 
HISTORY OF THYROID DISORDERS 3(6%) 
 
In our study group of 50 patients, 7 gave a history of previous episode of IHD and 4 
gave a history of TIA/stroke 
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CLASSIFICATION BASED ON BMI 
Table no 10 
 
Out of 50 patients, 48 % were overweight and 10% belonged to class 1 obesity.62% of 
the female patients with ACS has deranged BMI. 
Figure no 6
 
2% 
36% 
48% 
10% 
2% 2% 
BODY MASS INDEX 
underweight 
normal 
overweight 
class 1 obesity 
class II obesity 
class III obesity 
BODY MASS INDEX NO OF PATIENTS (n=50) 
<18.5 1 
18.5-24.9 18 (36%) 
25-29.9 24(48%) 
30- 34.9 5(10%) 
35-39.9 1(2%) 
>40 1(2%) 
 
 
 
 
78 
 
 
FASTING LIPID PROFILE 
Table no 11: high density lipid profile 
HDL (mg/dl) No of patients (n=50) 
<20 1(2%) 
20-30 24(48%) 
30-40 17(34%) 
40-50 7(14%) 
>50 1(2%) 
 
In the study, 50 % of female patient had a HDL value below 30. 
Table no 12: low density lipid profile 
LDL(mg/dl) No of patients(n=50) 
<130 19(38%) 
130-160 11(22%) 
>160 20(40%) 
 
 In the study, 40% of the study group had a LDL value above 160mg/dl. 
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CLASSIFICATION OF ACS PATIENTS BASED ON ST ELEVATION IN ECG  
Table no 13: distribution of STEMI in the study group 
ST elevation (STEMI) 30(60%) 
No ST Elevation 20(40%) 
TOTAL NO OF PATIENTS 50 
 
30 out of the 50 female patients in the study group were diagnosed to have STEMI , 
while the remaining 20 had NSTEMI/UA. 
Table no 14: classification of STEMI according to area affected 
ECG finding(area affected) No of STEMI patients n= 30 
IWMI 12(40%) 
ASMI 5(16%) 
ALMI 2(6%) 
AWMI 6(20%) 
IWMI + RWMI 3(10%) 
IWMI + RWMI + PWMI 2(6%) 
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Table no14: Classification of ACS patients with troponin test 
TROPONIN TEST  NO OF PATIENTS (n=50) 
Positive result 38 
Negative result 12 
 
Table no 15: Classification of patients with no ST segment elevation with troponin 
test 
TROPONIN TEST  NO OF PATIENTS (n=20) 
Positive result(NSTEMI) 8 
Negative result(UNSTABLE ANGINA) 12(60%) 
 
Out of 50 patients diagnosed with acute coronary syndrome, 60% had STEMI. IWMI 
was the leading finding in ECG of 40% patients with STEMI. 
76% of the patients were Trop T positive, out of which 16% was contributed by 
NSTEMI patients. 
Out of 30 STEMI patients, 25 were thrombolysed. The remaining 5 did not undergo 
thrombolysis due to various reasons. 
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Figure no 7 Pie chart distribution of ACS
 
 
KILLIP STAGING 
Killip staging was done for patients with MI. 55.2% of the patients belonged to Killip 
class I. 
Table no 16 
KILLIP STAGING NO OF PATIENTS(n=50) 
Killip class I 21(42%) 
Killip class II 6(12%) 
Killip class III 6(12%) 
Killip class IV 5(10%) 
  
STEMI 
60% 
NSTEMI 
16% 
UNSTABLE 
ANGINA 
24% 
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ANALYSIS OF RESULTS 
This was a cross sectional study done on 50 patients who were admitted with acute 
coronary syndrome. Out of the 50, 78% (39) had presented with chest pain and 30.7% 
of these 39 patients gave the typical history of angina pain. 18% &20% gave the 
history of nausea and vomiting respectively. No chest pain was reported by 22% (110 
of the study group.  Out of these 11 patient 72.7% (8) were above the age of 60 years 
.82% of those without chest pain were known diabetics 
 
The most common sign was crepitations or basal crackles (30%). 8 %( 4) of the 
patients had hypotension while 10% had hypertension at the time of presentation. S3 
was heard in 12% of the study group and 22% (11) had extensive crackles (pulmonary 
edema) 
Most of the patients belongs to the age group of 45 to 50 years (54%) and 34% (17) 
belongs to the age group of 60 to 75 years 8% (4) were above the age of 75 
In this study 32% (16) had diabetes out of which 285 (140 were diagnosed with 
diabetes >10years while 4% were diagnosed diabetes <10 years. 50% (25) of the study 
group were diagnosed as hypertensive patients 
Out of 50 female ACS patients 88% (44) had attained menopause were 12% were in 
the pre menopausal age group.16 %( 8) of the female patients gave appositive history 
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of OCP use on a regular basis. While one out of 50 gave a history of alcohol use and 
18 %( 9) gave a history of tobacco use. 
50%(25) of the female patients were found to have sedentary life style 44% (22) and 
6%(3)were found to be moderate and heavy workers respectively.6%(3)were gave a 
history of regular exercise and  8% gave a history of irregular exercise.4%(2) were 
found to have dietary planning. Majority of the patients i.e. 82 %( 41) did not follow 
dietary planning nor exercise. 
8 %( 4) 14 %( 7) and 6 %( 3) gave past history of TIA, IHD and thyroid disorders 
respectively 
Out of 50 patients 48%(24) were found to have a BMI of 25 – 29.9 and 36%(18)had a 
normal BMI OF 18.5 -24.9.10%95),2%(1)and 2%(1) belongs to class 1 ,class2 and 
class 3 obesity respectively. 
48%(24) had an HDL  20-30 mg/dl and 34%(17) had an HDL of 30 -40 only 2%(1) 
had desirable HDL value of >50 mg/dl.40%(20) of the female ACS patients had an 
LDL level of >160 mg/dl.38%(19) and 22%(11)had a LDL value of <130 and 130 -
160 mg/dl respectively 
Out of 50 patients I this study group 60%(30) had STEMI.40%(12) of the 30 STEMI 
patients had IWMI 20%(6) had AWMI 16% (5) 6(2)and6%(2) had ASMI 
,ALMI,IWMI RVMI AND PWMI respectively. 
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76% of the patients were Trop t positive out of which 16% was contributed by 
NSTEMI.24% (12) of the 50 patients had unstable angina. Out of the 30 STEMI 
patients 25 were thrombolysed 
According to Killip staging 42 %( 21) belong to class 1 and 10% (5) belongs to class 4 
the remaining 24% belongs to class 2 and 3 equally. 
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DISCUSSION 
 
Acute coronary syndrome in females has become a real challenge for both physicians 
and cardiologists. Most of the data regarding the risk factors of ACS is based on 
studies conducted in men. 
According to various studies done around the world cardiovascular disease is one of 
the leading causes of death in men and women. According to WHO report 55% deaths 
in European females is related to ACS as compared to 43% in men. However the 
mortality from CVD has declined in the developed countries from 1970 to 2015 while 
it has doubled in the developing countries. 
In a study by V.  Chiamvimonvat and L. Sternberg (University of Toronto): 
Coronary artery disease is the leading cause of mortality in women, with incidence 
after menopause equal to that of men. Diabetes and postmenopausal status without 
Hormone replacement therapy is the strongest risk factors. 
It has been reported that people of the South Asian descent has a higher incidence of 
coronary heart disease. Metabolic abnormalities like high TG concentration, type 2 
DM, low HDL and central obesity are also more prevalent in the people from Indian 
subcontinent 
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For men and women cardiovascular risk increases with age, smoking, obesity, 
hypertension and hyperlipidemia. In our cross sectional study of 50 females with 
ACS, 54% belongs to the age group of 45 to 60 years. The number of female 
patients above 75 years was only 8%, while 34% of study group belongs to 60 -75 age 
group. This discrepancy can be attributed to poor hospital reporting and increased 
mortality among the ACS female patients above 75 years. 
The coronary risk factors in both sexes are the same but after menopause their 
influence on women is different. This is due to the female specific hormonal changes 
during menopausal period. The data collected from POLISH ACS registry revealed 
that women with ACS were older than men by 7.7 years. In our study, 88% of the 
female patients had attained menopause and this was clearly indicative of the age 
related and hormonal influence on the incidence of ACS . 
In our study, 78% of the patients had chest pain where as 22% did not give a typical 
history of chest pain or angina; 38% of the study group had symptoms of nausea and 
vomiting and 20% had palpitations.  
Out of the 11 patients without chest pain, 9 were diabetic. This observation is in 
accordance with various studies which showed the prevalence of atypical symptoms in 
diabetic individuals. 
In a study by Marrugat et al., (1998) women are at a higher risk of having symptoms 
such as nausea, instead of chest pain. 
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Out of 50 patients, 32% were found to have crepitations, while 24% patients had 
pulmonary oedema or extensive crackles. 
According to the CHINESE ACS registry, 24.4 % of women were significantly older 
than male patients and the prevalence of diabetes and hypertension were higher in the 
female group compared to the male group. Similar observations are seen in other 
worldwide registries also. In our cross sectional study of 50 patients, 16 were diabetic 
and out of which 14 patients were known diabetic for more than 10 years 
Women with diabetes had a 3.5times increased cardiovascular related mortality 
as compared to non diabetic women according to Huxley et al. 
Diabetes confers substantial increased relative risk of first incident and admission for 
MI in women compared with age-to-sex matched controls younger than age 65 yrs 
over a 20 year follow up in Copenhagen City Heart Study. 
 
In our study 50% of the patients were hypertensives. Along with high salt intake, 
genetic factors, obesity and psychological stress plays an important role in the 
development of hypertension. Hypertensive patients had an increased morbidity and 
mortality following a cardiovascular incident. 
An interesting finding is that women smokers have a six fold increased risk of ACS 
compared to a non-smoker female, while smoking men only had a threefold risk 
increase. This can be attributed to the effect of nicotine on the oestrogen level. In our 
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study of 50 patients, 2 gave a positive history of smoking and 7 gave a history of 
tobacco chewing. 
A study by Liaquat Ali Cheema et al., (Gender comparison of coronary risk factors 
and clinical presentation in Pakistani patients with coronary artery lesions): This 
showed that smoking was not a risk factor in females in the study population and 
diabetes mellitus was more common in females while smoking and dyslipidemia in 
males. However this can be attributed to cultural and social differences also. 
Mosca et al study: In this study, compared with male patients, out of the total female 
patients, 41% were identified to be overweight, 36% said smoking, 31% cited high 
cholesterol, 29% identified family history, 19% said hypertension, 19% identified 
diabetes and 1% had high triglyceride level (Mosca et al., 2004). 
 
In our study 48% were overweight and 10% belongs to class 1 obesity and 36% of 
the patients had a normal BMI. The importance of activities in the prevention of 
cardiovascular disease is evident in this study group.  
In our study, 50% of the female patients led a sedentary life style (activities based on 
occupation) while 3 out of the fifty people were heavy workers. 82% of the female 
patients did not follow any life style modification and 2 out of the 50 patients had 
dietary planning and regular exercise. 
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In the Nurses’ Health Study, both BMI >25 and physical activity were important 
predictors of coronary artery disease in 20 year follow up.  
In men, high LDL levels were found to have a strong prognostic impact where as in 
women the role of low HDL is more important. Independent of the serum LDL and 
TG levels, women with low HDL levels had a higher risk for CVD. The risk of CAD 
decreases by 3% for every 1 mg/dl increase in HDL in women but only 2% in men.  
In this study, 20 (40%) out of the 50 patients had an LDL above 160, while 
favourable lipid profile was seen only in 19 patients. 50% of the study group had 
HDL values below 30. 
In its recent guidelines, the American Heart Association(AHA) has changed the cut-
point for what constitutes low HDL-C in women from less than 40 to less than 50. 
 
Recently published data on mortality from coronary heart disease have shown an 
increase in the mortality of women between 35 &45 years. Also coincident with this 
observation, there is more frequent use of OCPs among this age group. In our study of 
fifty patients, 8 females had a history of OCP use. 
In this study, menopause was found to be the most prevalent risk factor (i.e.  88% of 
the total) followed by dyslipidemia. A low HDL value (i.e. 50% of the total) was 
found to be more prevalent than a high LDL value. The next important risk factor 
according to this study was a deranged body mass index. This was followed by 
hypertension, diabetes and tobacco use. 
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CONCLUSION 
The following are conclusions that could be inferred from this study on clinical 
spectrum and risk factors among female patients. 
 The most significant risk factor was age, followed by dyslipidemia and 
abnormal BMI. 
 The most common age group affected was 45-60 years  
 Most of the female patients had attained menopause. This highlights the 
importance of hormonal influence on ACS. 
 Most of the patients had a low HDL value below 30mg/dl and LDL above 
160mg/dl 
 Diabetes and hypertension are clearly associated with an increased risk for 
ACS. 
 Obesity, sedentary lifestyle and lack of exercise are also important risk factors 
for ACS 
 Tobacco and OCP use also can be considered as risk factors in the development 
of ACS. 
 The most common symptom was chest pain. Atypical symptoms were more 
prevalent among diabetics and the elderly 
 Most of the patients had STEMI, followed by unstable angina. 
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PROFORMA 
NAME                                                        
     AGE   
    DOA 
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    DOD                                        
    MARITAL STATUS                                          NO OF CHILDREN 
ADDRESS                                                       
    OCCUPATION 
FAMILY INCOME/YEAR 
PRESENTING SYMPTOM: Chest pain / Nausea / vomiting / Epigastric pain / Jaw 
pain / Left arm pain / Sweating/ Dyspnoea / Palpitation / Syncope / Others 
DURATION OF SYMPTOMS : 
PAST HISTORY : 
 PAST H/O IHD 
 TIA/STROKE 
 HYPERTENSION: YES/ NO            TREATMENT 
 DIABETES: YES/ NO                       TREATMENT 
 HYPERLIPIDEMIA: YES / NO          TREATMENT 
 THYROID DISORDERS : YES/ NO 
 RHEUMATOLOGICAL / CONNECTIVE TISSUE DISORDERS: 
 SYPHILIS: 
 SMOKING: YES/NO 
 ALCOHOL: 
 CHRONIC DRUG INTAKE / OCP: 
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 PHYSICAL ACTIVITY: 
FAMILY HISTORY OF IHD: 
MENSTRUAL HISTORY:  
MENOPAUSE:     YRS SINCE MENOPAUSE 
DIET HISTORY:   VEG/NON VEG 
TYPE OF COOKING OIL: 
SALT INTAKE: 
COFFEE/ TEA: 
 CLINICAL EXAMINATION 
HT 
WT 
BMI 
BP: 
PR: 
Anemia: 
Cyanosis: 
Clubbing: 
Icterus: 
Pedal edema: 
Markers of Hypercholesterolemia 
CVS: 
RS: 
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P /A: 
CNS: 
LABORATORY INVESTIGATIONS 
1.  Urine R /E:  
Albumin 
Sugar 
Deposits 
2. RFT: Urea 
Creatinine 
Electrolytes 
3. CBC: Total Count                           Differential Count 
Erythrocyte Sedimentation Rate 
Hemoglobin                 Platelets 
4. RBS 
5. LIPID PROFILE 
TOTAL CHOLESTEROL mg/dl  
HDL CHOLESTEROL mg/dl  
LDL CHOLESTEROL mg/dl  
VLDL CHOLESTEROL mg/dl  
TRIGLYCERIDE mg/dl 
6. Serum Troponin -T:  
7. Electrocardiogram: 
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8. Echocardiogram: 
OTHER RELEVANT INVESTIGATIONS  
DIAGNOSIS  
THROMBOLYSIS - DONE/NOT DONE  
IN HOSPITAL COMPLICATIONS  
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LIST OF ABBREVIATIONS  
 
ACS – Acute coronary syndrome 
AMI– Acute myocardial infarction  
AF– Atrial Fibrillation  
CAD – Coronary Artery Disease  
CCF – Congestive Cardiac Failure  
CHD – Coronary Heart Disease  
CK-MB – Creatinine Kinase-MB  
CVD – Cardiovascular diseases  
ECG – Electrocardiogram  
IHD – Ischemic Heart Disease  
LVF – Left ventricular Failure  
MR – Mitral Regurgitation  
MI – Myocardial infarction  
RBS – Random Blood Sugar  
SA– Sinoatrial node  
STEMI – ST Elevation myocardial infarction  
VT – Ventricular Tachycardia  
WBC – White Blood Cell 
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    Sl 
    no       
IP no age      symptoms    DM 
 
HT
N 
PRIOR  
IHD 
TIA/ 
STROK
E 
RHD/ 
SLE 
THYRO
ID 
Meno
pause, 
OCP 
use 
C 
P 
EP p
al 
d
ys 
o
t
h 
<10 
YRS 
>10
YRS 
1 3980 53 N N Y N N N Y N N N N N M,ocp 
2 4011 57 Y N N Y Y Y N N N N N  Y M,nil 
3 4078 76 N N Y Y Y N Y Y N Y N N M,nil 
4 4678 62 Y Y N Y N N N N N N N N M,nil 
5 5789 58 Y N Y N N N N Y  Y N N N M,nil 
6 5999 65 Y N N Y Y N N N N N N N M,nil 
7 7120 52 Y N N N N N N Y N N N N M,nil 
8 7130 53 Y Y N N N N N N N N N N M,nil 
9 7390 66 N N Y Y N N Y Y Y N N N M,nil 
10 7780 43 Y N N N N  Y N N N Y N N -,ocp 
11 7990 55 Y N N  N N N N N N N N N M,nil 
12 8000 77 N N Y Y Y N Y N N N N N M,nil 
13 8012 59 Y Y N Y N N N Y N N N N M,nil 
14 8027 58 Y N N N N N N Y N N N N M,nil 
15 8456 62 Y N N N N N N N N N N N M,nil 
16 8678 49 N N Y Y Y N Y Y N N N N M,nil 
17 8654 72 Y Y N N N N N N Y N N N M,nil 
18 3456 53 Y N N N Y N Y N N N N  Y M,nil 
19 8790 56 Y Y N Y N N N Y N N N N M,nil 
20 8890 47 Y N N N Y N N N N N N N -,ocp 
21 4567 59 Y N N N Y N N Y N N N N M,nil 
22 4890 66 Y Y N Y N N N Y N N N N M,nil 
23 9000 54 Y N N N Y N Y N Y N N N M,nil 
24 9044 42 Y N N Y N N N  Y N N N N -,nil 
25 9051 72 Y N N N Y N N N N N N N M,nil 
2   26 9160 76 N N N N N N Y N N N N N M,nil 
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27 9340 57 Y N N N N N Y Y N N N N M,ocp 
28 9567 68 Y N N N Y N Y Y N N N N M,nil 
29 9890 64 Y N N N N N Y N N N N N M,nil 
   30 10012 70 N N N N N N y Y N N N N M,nil 
31 10056 59 Y Y N N Y N N N N N N N M,nil 
32 5342 67 N N Y Y N N N Y N N N N M,nil 
33 5129 59 Y N N Y Y N N Y N N N N M,nil 
34 10067 60 Y N N N N N N Y N N N N M,ocp 
35 10789 48 Y Y N Y Y N N N N N N N M,nil 
36 10986 55 Y N N N N N N N N N N N M,nil 
37 11198 73 Y N N Y N N N Y Y N N N M,nil 
38 9410 50 Y Y N N Y N N Y N N N N M,nil 
39 11567 52 Y Y N Y Y N N N N N N Y M,nil 
40 14567 65 Y N N N N N N Y N N N N M,nil 
41 15378 53 Y N N N N N N Y N N N N M,nil 
42 15563 48 Y N N N Y N N N N N N N -,ocp 
43 15768 79 N N Y Y N N Y Y  Y  Y N N M,nil 
44 15890 63 Y N N Y Y N N N N N N N M,ocp 
45 15967 58 Y N N N N N N Y N N N N M,nil 
46 15980 73 N N N N N N N Y   Y N N N M,nil 
47 16000 59 N N N Y N N Y N N N N N M,nil 
48 16008 52 Y N N N N N N Y N N N N M,nil 
49 16120 49 Y N N Y Y N N N N N N N -,ocp 
50 16759 68 Y N N N N N N N N  Y N N M,nil 
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Sl.no ALC/ 
SMOK 
BMI               SIGNS HDL  LDL RBS ECG TROP 
T 
Thrombolys
bolysed 
 
Hyp 
er T 
Hyp 
o T. 
S3 S4 JVP Cre 
ps 
P  
E 
 
KILL 
IP 
physical activity 
1 N 21 N Y Y N N Y Y IV 42 170 112 IWMI + Y sedentary 
2 N 25.5 Y N N N N N N  I 52 180 100 ALMI + Y sedentary 
3 N 20.6 N N N N N N Y III 38 109 176 AS MI + N moderate 
4 N 24 Y N N N N N N I 27 180 167 AWMI + Y sedentary 
5 N 26 N Y N N N Y Y IV 36 169 140 AWMI + N sedentary 
6 TOB 27.6 N N N N Y Y Y III 49 172 146 IW+RWMI + Y sedentary 
7 N 33.6 N N N N N N N II 34 110 112 IWI +  Moderate  
8 N 34.1 N N N N N N N  24 164 166 IWI -  heavy 
9 N 38.1 N Y N N Y Y Y IV 44 119 157 IW+RWMI + N sedentary 
10 N 25.4 N N N N N Y Y III 38 180  116 AWMI + Y moderate 
11 N 29 Y N N N N N N I 47 178 80 ALMI + Y moderate 
12 N 25.2 N N N N N N N I 35 172 244 IWMI + Y sedentary 
13 N 26.6 N N N N N Y N II 42 182 95 AWMI + Y moderate 
14 N 28.7 N N N N N N N  32 189 89 IWI -  sedentary 
15 TOB 34 Y N N N N Y N I 38 192 134 IWI +  sedentary 
16 N 25 N N N N N Y Y IV 46 176 224 IWMI +  Y sedentary 
17 N 22 N N Y N N Y Y III 47 189 226 IWMI + N moderate 
18 TOB 26.1 N N N N N N N  33 172 119 AWI -  sedentary 
19 N 31 Y N N N N N N I 36 194 212 IWMI + Y sedentary 
20 N 25.2 N N N N N Y N II 48 179 134 AWMI + Y sedentary 
21 N 41 N N N N N N N  34 116 117 AWI -  moderate 
22 SMOK 27 N N N N N N N I 28 180 116 IWMI + Y sedentary 
23 N 26.2 N N N N N N N  36 120 108 AWI -  sedentary 
24 N 26.7 N N N N N N N I 31 119 226 AWI +  sedentary 
25 TOB 19.8 N N N N N N N  44 100 118 AWI -  moderate 
26 N 21 N N N N N N N  37 88 150 AWI -  moderate 
27 N 20.8 N N N N N N N  26 156 80 IWI -  sedentary 
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28 N 25.7 N N Y N N Y N II 39 110 200 IWMI + Y moderate 
   29 N 27.7 N N N N N N N I 44 144 86 ASMI + Y sedentary 
30 N 27 N Y N N N N Y IV 37 176 188 ASMI + Y sedentary 
31 ALC 20 N N Y N N Y Y III 49 177 250 AWI +  sedentary 
32 SMOK 25.6 N N N N N N N I 33 174 100 IWMI + Y moderate 
33 N 22 N N N N N Y N II 42 112 85 IWI -  moderate 
34 N 26 N N N N N N N I 38 165 207 RW+PW+IW + Y moderate 
35 TOB 29 N N Y N Y Y Y III 27 142 170 IW+RWMI + Y moderate 
36 N 27.2 N N N N N N N  36 137 117 AWI -  heavy 
37 N 24.8 N N N N N N N I 38 158 109 IWMI + Y moderate 
38 TOB 21 N N N N N N N I 39 119 120 IWMI + Y moderate 
39 N 19.4 N N N N N N N I 35 174 160 AWMI + Y moderate 
40 N 25 N N N N N N N I 32 177 152 AWI +  sedentary 
41 N 24.5 N N N N N N N I 28 139 121 IWI +  sedentary 
42 TOB 32 N N N N N N N  47 104 92 IWI -  sedentary 
43 N 20.1 N N N N N N N  36 139 208 AWI -  heavy 
44 N 24 N N N N N N N I 33 179 230 ASMI + Y moderate 
45 N 25.2 N N N N N N N I 39 179 137 AWI +  sedentary 
46 SMOK 21 N N N N Y N N I 43 118 200 IWMI + N moderate 
47 N 26.3 N N N N N N N I 42 167 156 IWI +  moderate 
48 N 19.7 N N Y N N Y N II 36 176 87 ASMI + Y sedentary 
49 N 22 N N N N N N N I 31 111 100 IWMI + Y sedentary 
50 N 18.4 N N N N Y N N I 47 118 80 PW+RW+IW + Y moderate 
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KEY to MASTER CHART 
Y = yes 
N = no 
CP= chest pain 
EP= epigastric pain 
Pal = palpitation 
Dys = dyspnoea 
OCP = oral contraceptive pill 
M = menopause 
ALC = alcohol 
Smok = smoking 
Tob = tobacco chewing 
ASMI = anteroseptal mi 
AWMI= anterior wall mi 
IWMI = inferior wall mi 
ALMI = anterolateral mi 
RVMI= right ventricular mi 
PWMI = posterior wall mi 
PE =pulmonary oedema 
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 CONSENT FORM  
 
 
 
 
 
I __________________________________________ hereby give consent to 
participate in the study conducted by DR SOBIN E.JOSEPH Post graduate in the 
Department of General Medicine ,Thanjavur Medical College & Hospital, Thanjavur 
– 613004 and to use my personal clinical data and result of investigation for the 
purpose of analysis and to study the nature of disease. I also give consent for further 
investigations  
Place :  
Date :                                                                                     Signature of participant 
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INFORMATION SHEET 
 
We are conducting a cross sectional study on THE PREVALENT RISK FACTORS 
OF ACS IN FEMALES 
 in the Department of General Medicine , Thanjavur Medical College & Hospital, 
Thanjavur – 613004. 
 
 At the time of announcing the results and suggestions, name and identity of the 
patients will be confidential. 
 
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
 
 The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment.  
 
 
 
 
 
 
 
Signature of investigator  Signature of participant 
 
Date: 
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